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Abstract
Background: We describe the prevalence of invasive carbapenem-resistant Acinetobacter spp. isolated from
2005 to 2016 in different regions of Switzerland.
Methods: Using the Swiss Antibiotic Resistance Centre (anresis) database that includes data from 70% of all
hospitalized patients and one third of all ambulatory practitioners in Switzerland, we analysed the number of
carbapenem-susceptible and resistant Acinetobacter spp. isolated from blood or cerebrospinal fluid, and further
described their temporal and regional fluctuations.
Results: From 2005 to 2016, 58 cases of resistant or intermediate strains to carbapenem were observed among
632 cases of invasive Acinetobacter. Multivariable analyses indicated that the number of carbapenem-resistant
isolates (mean 4.8 ± sd 2.12) and carbapenem resistance rates per region per annum (8.4% ± 13.9%) were low
and stable over the studied period. Large fluctuations were observed at the regional level, with e.g. the North
East region displaying resistance rates twice as high as that found in other regions.
Conclusion: Despite a relatively stable number of carbapenem-resistant Acinetobacter isolates in Switzerland,
our results suggest the existence of a diverse pool of A. baumannii species in hospital settings, and confirm the
implication of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex in the
vast majority of clinical infections and nosocomial outbreaks with notable regional fluctuations.
Keywords: Carbapenem resistance, Acinetobacter baumannii complex, Surveillance, Epidemiology, Temporal
trends, Regional trends
Background
In the Gram-negative, strictly aerobic Acinetobacter genus,
the species that mostly present a risk as opportunistic
human pathogens are A. baumannii, A. nosocomialis, A.
pittii, A. calcoaceticus, A. seifertii and A. dijkshoorniae,
which belong to the so-called Acinetobacter calcoaceticus-
Acinetobacter baumannii (ACB) complex. Generally, these
four species are not well differentiated at the phenotypic
level [1]. They represent the most relevant species clinic-
ally, as they may cause serious, difficult-to-treat infections
in patients in healthcare settings [1, 2], and are prevalent
in the European Union / European Economic Area
countries. In contrast, “non-ACB” Acinetobacter species
generally present lower pathogenicity and are often
found in the environment. Yet, uncommon and oppor-
tunistic non-ACB Acinetobacter species, such as A.
ursingii, may also cause bloodstream infections [3, 4].
Over the last years, the epidemiological situation has
worsened in Europe and worldwide with reports of
inter-regional spread and endemic establishment of A.
baumannii resistant to carbapenems, a last-line group
of β-lactam antibiotics used to treat patients infected
with multidrug-resistant Gram-negative bacteria [5–8].
Here we report on the temporal and regional analysis
of invasive carbapenem-resistant Acinetobacter isolated
in Switzerland from 2005 to 2016.
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Methods
Antibiotic susceptibility results (AST) were extracted
from the database of the Swiss Antibiotic Resistance
Centre (anresis.ch) on 8 June 2017. This database in-
cludes all AST results from 20 participating laboratories,
representing about 70% of all hospitalized patients and
one third of all ambulatory practitioners. The laborator-
ies are geographically spread over all Swiss regions and
include private, university and general hospital labora-
tories. These laboratories send all results from routine
testing of clinical bacteriology cultures to the anresis
database on a regular basis (weekly or monthly). In con-
trast to other surveillance systems, all antimicrobial
resistance results are sent to the anresis database, not
restricting the data either to invasive isolates or to spe-
cific microorganisms. To allow for higher comparability
with international reports, we therefore used the same
approach as in the antibiotic surveillance systems of the
ECDC (EARS) and of the WHO-Europe (CASEAR),
which restrict their analyses to invasive isolates from
blood cultures or cerebrospinal fluid. Duplicate entries
were removed and only the first date of occurrence of
Acinetobacter isolation in case of re-infected patients
was kept for a given year. Isolates from foreign countries
were excluded.
We used the interpreted, qualitative data (SIR) deliv-
ered by the participating laboratories, as most microbio-
logical laboratories send only qualitative, interpreted
resistance data (SIR). SIR data are not validated by
anresis.ch but by the laboratories sending the data. All
laboratories participating in anresis.ch are approved and
participate in at least one external quality program from
NEQAS (https://ukneqas.org.uk/) or from the Quality
Control Center Switzerland (http://www.cscq.ch). Iso-
lates are classified as susceptible, non-susceptible or
intermediate to at least one of imipenem or meropenem
following clinical breakpoints of the given years pub-
lished in the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines (www.eucast.
org) or, according to the Clinical and Laboratory Stan-
dards Institute document M31-A3 (CLSI). Most of the
participating laboratories switched from CLSI to EUCAST
breakpoints between 2011 and 2013.
In addition to SIR data, local laboratories provide ac-
companying epidemiological information, such as sample
location, provider of the sample, patient sex and
age-group, but no clinical data about diagnosis, therapy or
outcome. Isolate prevalence was modelled via Generalized
Poisson regression and resistance rates via logistic regres-
sion, with year and regions as explanatory variables. We
calculated 95% confidence intervals using robust standard
errors for the parameter estimates of the Generalized
Poisson regression [9]. Analyses and visualization were
done with the R statistical environment (version 3.3.2).
Results
From 2005 to 2016, a total of 800 invasive Acinetobacter
isolates were identified in the anresis.ch database, consisting
of 707 carbapenem-susceptible and 93 carbapenem-
resistant isolates, respectively. After removal of duplicates,
58 resistant or intermediate isolates were identified out of
632 cases (resistance rate 9.2%) over the study period
(Table 1). Four out of 58 carbapenem-resistant isolates were
isolated from cerebrospinal fluid, the rest from blood cul-
tures. Co-resistance to other antibiotics, such as aminogly-
cosides (47/55, 86%), trimethoprim-sulfamethoxazole (42/
54, 78%) and fluoroquinolones (47/55, 86%), was high,
whereas no colistin-resistance was reported for 23 isolates
tested. There was a significant increase in the total number
of Acinetobacter isolations over time (linear regression,
F = 21.56, P < 0.001, R2 = 0.65) with 32.1 isolates per
year on average (t = 6.39, P < 0.001), increasing at a
yearly rate of 3.2 new isolates (t = 4.64, P < 0.001).
When ACB complex species were only considered,
there was 18.6 isolates per year on average (t = 5.62, P
< 0.001), increasing at 0.98 (t = 2.17, P = 0.055) new
isolates per year. The largest number of resistant
isolates belonged to the ACB complex (55/299, 18.4%),
while resistance rates were much lower in species not
belonging to the ACB complex (1/184, 0.5%). For
Acinetobacter isolates not typified at species level, 2 out
of 149 (1.3%) were carbapenem resistant (Table 1).
Generalized Poisson regression of the number of
carbapenem-resistant isolates on year (from 2005 to
2016) and across 8 Swiss regions indicated that year has
no significant effect on the average of 4.83 (sd 2.13) total
Acinetobacter isolates per year or on the number of ACB
isolates (average 4.58 sd 2.11), with incident rate ratios
[IRR] of 1.00 (95% CI 0.96–1.04, P > 0.050) for both
ACB and non-ACB isolates (Additional file 1: Table S1).
The North East region, with a total of 24 resistant Acine-
tobacter (22 of which were ACB) isolations from 2005 to
2016, was significantly above all other regions in terms
of number of resistant isolates, e.g. the comparison with
Centre East (2 isolates, both ACB) taken as the reference
region yielded IRR = 2.00 (1.35–2.98), P < 0.001 (for ACB
only, values were IRR = 2.19 (1.46–3.28), P < 0.001).
Other regions with 4.9 (sd 2.5) carbapenem-resistant
Acinetobacter isolates on average were not significantly
different from Centre East (P > 0.05).
Those trends were confirmed when examining resist-
ance rates per year per region (Fig. 1a, b), which reached
8.4% (sd 13.9%) on average, and for ACB isolates 15.4%
(sd 26.1%). There was no significant temporal trend in
resistance rates (for all Acinetobacter isolates, OR 1.06
(0.98–1.16), P = 0.155; for ACB isolates only, OR 1.08 (0.
99–1.19), P = 0.096). Only the North East region (resist-
ance rates for all Acinetobacter isolates of 23.4% sd 22%;
for ACB isolates, 32.9% sd 30.7%) had higher rates on
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average (OR 6.75 (1.88–43.32), P = 0.012; for ACB iso-
lates, 4.95 (1.24–33.3) P = 0.045) than region Center East
(resistance rate 4.4% sd 10.8%; for ACB isolates, 11.1%
sd 29.6%). Other regions had resistance rates ranging
from 1.3 to 13.0% (2.1 to 19.8% for ACB isolates),
which were not significantly different from that of
Center East (P > 0.05).
At a more detailed level of analyses (daily resolution,
Fig. 1c; and resistance rate per region per year, Fig. 1d),
number of cases and carbapenem-resistance rates associ-
ated with Acinetobacter isolates displayed large temporal
and regional disparities, both displaying patterns remin-
iscent of outbreaks: the detailed analysis of the increase
in 2010 observed in the North East region was highly
suggestive of an outbreak because 5 resistant Acineto-
bacter isolations, all belonging to ACB, occurred for the
whole region within six weeks in the same intensive care
unit of burn patients.
We tested the effect of the variation in laboratories
contributing to the anresis database on our conclusions
by using the data provided by the 14 laboratories that
always sent data from 2005 onwards. This sensitivity
analyses showed that the number of resistant isolates
and resistance rates over year and region did not change
qualitatively as compared to the results obtained with
the complete dataset (Additional file 1: Table S1): The
number of total resistant isolates in the sensitivity ana-
lyses did not significantly increase over time and the
North East region displayed higher number of isolates
than any other region, considering all Acinetobacter iso-
lates or only ACB isolates (Additional file 1: Table S1).
Similarly, the sensitivity analysis of the factors affecting
resistance rates also confirmed that there was no signifi-
cant temporal changes for all Acinetobacter isolates and
when considering ACB isolates only (the temporal trend
was marginally significant for ACB with P = 0.042;
Additional file 1: Table S1), and that the North East
region had higher rates on average than other regions
(resistance rates in the sensitivity analyses ranging
from 1.0 to 11.1 and 0 to 24.0% for ACB isolates).
Fig. 1 a Acinetobacter resistance rates (number of resistant isolates compared to total number of isolates) per region from 2005 to 2016 in Switzerland.
Standard deviation bars represent annual fluctuations per region. b Map of the Swiss regions defined in this study. The original map template, which was
made freely available by the Federal Statistical Office (https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/maps.html), was modified by the
authors. c Frequency of isolation of resistant Acinetobacter across Swiss regions from 2005 to 2016 (daily resolution). d Acinetobacter resistance rates per
year and per region in Switzerland
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Discussion
A publication by the ECDC of an article entitled “Carba-
penem-resistant Acinetobacter baumannii in healthcare
settings” [8], concluded that “there has been an overall in-
crease in carbapenem-resistant Acinetobacter baumannii in
Europe, especially in countries of lower prevalence.” Using
the database of the Swiss Antibiotic Resistance Centre (anr-
esis.ch), which includes all AST results representing about
70% of all hospitalized patients and one third of all ambula-
tory practitioners in Switzerland, we report on the first
nationwide surveillance study on invasive carbapenem-
resistant Acinetobacter isolated from 2005 to 2016 in
Switzerland. Importantly, we observed that the resistance
rate has stabilized yearly at 8.4%, with large temporal and
regional disparities, but without increase over time.
Our results indicate the existence of a diverse pool
of A. baumannii and related species in hospital set-
tings in Switzerland, as also observed in France [10].
We confirmed the implication of carbapenem-resistant
ACB complex isolates in the vast majority of clinical
infections and nosocomial outbreaks that involved Aci-
netobacter isolates, as observed previously in Germany
over a 5-year period [11]. Our findings were also in
agreement with the known higher risk of infection by
A. baumannii in burn patients in hospital settings, as
already reported in Switzerland [12] and in other
countries [13, 14].
The strengths of our study are that analyses were
based on data collected regularly and systematically over
10 years, covering a large proportion of hospitalized
patients in Switzerland. Limitations of our study include
the fact that there are no mandatory Swiss guidelines for
antibiotic resistance testing. Yet the Swiss Society of
Microbiology encourages the use of EUCAST break-
points and provides recommendations on their website
(http://www.swissmicrobiology.ch). Nevertheless individ-
ual laboratories are free to use other guidelines and
methods than EUCAST. Although most laboratories
initially based their testing on CLSI guidelines, they
changed to EUCAST guidelines between 2011 and 2013,
with in general an increased use of automated systems
over the years. Therefore identification methods may dif-
fer between different laboratories. Another limitation is
the fact that clinical isolates were classified as “suscep-
tible”, “intermediate”, or “resistant” based on clinical
breakpoints. As such, quantitative resistance data are
not available for most isolates. This classification indi-
cates the likelihood of a therapeutic success (e.g. dosing,
method and route of administration, pharmacokinetic
and pharmacodynamics) with a certain antibiotic and
thus helps the attending physician to select the best pos-
sible treatment. The use of different clinical breakpoints
(e.g. EUCAST vs. CLSI) or changing breakpoints over
time may therefore influence the results. However with
the change from CLSI breakpoints to EUCAST break-
points (as performed by most of the anresis-laboratories
between 2011 and 2013) we would expect a
methodology-related increase in resistance rates during
this time period, as breakpoints for susceptibility by disc
diffusion in EUCAST are higher than in CLSI 2009–
2011 (imipenem ≥23 vs. ≥16, meropenem ≥21 vs. ≥16,
respectively; [15]). This consideration strengthens fur-
ther our conclusion that carbapenem resistance in Aci-
netobacter did not increase over time in Switzerland.
Conclusions
Our analyses which cover both multiple years and multiple
regions conjointly highlight the usefulness of surveillance
approaches that integrate different temporal and spatial
resolution levels. Therefore, further surveillance efforts are
needed to detect and control Acinetobacter outbreaks, and
to limit the endemic establishment of resistant isolates in
additional health facilities and across EU regions.
Additional file
Additional file 1: Table S1. Sensitivity analyses of temporal and regional
trends in Acinetobacter and in ACB (number of isolates, resistance rates). We
compared the effects of year and region on the number of resistant isolates
and on resistant rates by considering data sent either by all laboratories or
by laboratories that regularly sent data since 2005. (DOCX 22 kb)
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